KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)

Healing & Recovery | 4 peptides | SAFETY GRADE C

KLOW peptide combines BPC-157, TB-500, GHK-Cu and KPV in one vial for tissue repair, gut healing and skin support. Dosage, benefits, side effects and evidence.

What Is in the Vial

BPC-157 | TB-500 | GHK-Cu | KPV

- The dosing table below describes the pre-blended 80 mg vial: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV, a 5:1:1:1 GHK-Cu : BPC-157 : TB-500 : KPV split.
- The ratio is fixed at manufacture. You cannot move one component without moving all four. Raising the blend dose raises GHK-Cu with it, and GHK-Cu is the limiting component.
- GHK-Cu sets the tier (1 to 2 mg per day, subcutaneous). GHK-Cu is 50 mg of the 80 mg vial, so it is 62.5 percent of every draw. The beginner tier of 2,000 mcg delivers 1,250 mcg GHK-Cu with 250 mcg each of BPC-157, TB-500, and KPV. Moderate (4,000 mcg) delivers 2,500 mcg GHK-Cu. Aggressive (4,800 mcg) delivers 3,000 mcg GHK-Cu, the top of the injectable range on the GHK-Cu page.
- Separate component vials: With separate vials you set each dose yourself and the 5:1:1:1 ratio no longer binds. Each range above comes from the component page on this site, and none of them has trial support for use in this combination. Pick with a prescriber. GHK-Cu 1 to 2 mg per day (community). Own page carries the full tier set. BPC-157 250 to 500 mcg per day (community). Own page carries the full tier set. TB-500 2 mg twice weekly (community). The twice-weekly schedule is the reason many users choose separate vials; a pre-blended vial forces a daily micro-dose instead. KPV 200 to 500 mcg per day (community). The published KPV work is oral dosing in mice (PMID 18061177); no human injectable dose has been established.
- Blend ratios are not standardized across products. Confirm the milligram breakdown on your COA before dosing. If your ratio differs, the component split above does not apply.

Dosing

TIER	BLEND DOSE	FREQUENCY	ROUTE	WHAT THAT DOSE DELIVERS
Beginner	2,000 mcg	Daily	SubQ	GHK-Cu 1,250 mcg, BPC-157 250 mcg, TB-500 250 mcg, KPV 250 mcg
Moderate	4,000 mcg	Daily	SubQ	GHK-Cu 2,500 mcg, BPC-157 500 mcg, TB-500 500 mcg, KPV 500 mcg. Above the ceiling stated by both consensus lines on this page (2,000 mcg per day total). Delivers 2,500 mcg GHK-Cu, above the 1 to 2 mg per day community range.
Aggressive	4,800 mcg	Daily	SubQ	GHK-Cu 3,000 mcg, BPC-157 600 mcg, TB-500 600 mcg, KPV 600 mcg. Above the ceiling stated by both consensus lines on this page. Delivers 3,000 mcg GHK-Cu, the top of the injectable range on the GHK-Cu page. It also delivers 600 mcg each of BPC-157 and KPV, above the 500 mcg per day top of the community range this page quotes for both. Do not exceed without prescriber oversight.

Every dose above is the total blend, not a per-component dose. Based on the 80 mg vial in 3 mL bacteriostatic water (26.7 mg/mL): 2,000 mcg = 7.5 units, 4,000 mcg = 15 units, 4,800 mcg = 18 units on a U-100 insulin syringe.

Cycle: 10 weeks on, 4 weeks off

Run daily injections for 10 weeks. Weeks 1 to 4 are the loading phase at the beginner dose, so the earliest a dose increase makes sense is week 5, and only if week 4 went well. Take 4 weeks off before repeating. Most users run 2 to 3 cycles per year. When pairing with GLP-1 agonists, start KLOW 1 to 2 weeks before the GLP-1 to establish a baseline of gut and tissue support.

Storage: 2-8°C (36-46°F) after reconstitution. Time to use after reconstitution varies by compound, so check the storage section on the peptide page rather than assuming a standard window.

Where This Dosing Comes From

COMMUNITY Community protocol combining multiple research peptides

Published research (confidence: none)

No clinical data exists for the four-peptide KLOW combination. Individual component evidence is preclinical (BPC-157, TB-500, GHK-Cu, KPV each have animal model data). First human BPC-157 IV safety pilot (Lee & Burgess 2025, PMID 40131143, n=2) showed tolerability up to 20mg IV; no efficacy claims possible from n=2.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

Community reports (confidence: weak)

Emerging community stack with anecdotal reports of improved skin elasticity, reduced GI symptoms on GLP-1 agonists, and faster soft-tissue recovery. Dosing is inconsistent across sources: community consensus (200-500mcg/day total blend, per community reports) diverges significantly from commercially marketed tiers (2000-4800mcg/day).

Reported by: Low Reddit signal (<50 dedicated threads); commercial blog and podcast coverage dominant

This protocol online: peptideschedule.com/peptides/klow-blend
KLOW Blend calculator: peptideschedule.com/calculator/blend/klow-blend-dosage-calculator
Protocol Planner (add to calendar): peptideschedule.com/protocol

For educational and reference purposes only. This is not medical advice. Consult a qualified healthcare provider before starting any peptide protocol. Peptide Schedule does not sell any product.